AQR Capital Management’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.28M | Buy |
136,540
+45,665
| +50% | +$428K | ﹤0.01% | 2052 |
|
|
2025
Q1 | $646K | Buy |
90,875
+55,118
| +154% | +$392K | ﹤0.01% | 2277 |
|
|
2024
Q4 | $417K | Buy |
+35,757
| New | +$417K | ﹤0.01% | 2341 |
|
|
2022
Q4 | – | Sell |
-5,048
| Closed | -$282K | – | 2252 |
|
|
2022
Q3 | $282K | Sell |
5,048
-3,230
| -39% | -$180K | ﹤0.01% | 1963 |
|
|
2022
Q2 | $428K | Sell |
8,278
-17,707
| -68% | -$916K | ﹤0.01% | 1735 |
|
|
2022
Q1 | $1.89M | Sell |
25,985
-14,715
| -36% | -$1.07M | ﹤0.01% | 1215 |
|
|
2021
Q4 | $4.81M | Sell |
40,700
-6,777
| -14% | -$801K | 0.01% | 839 |
|
|
2021
Q3 | $6.37M | Buy |
47,477
+11,901
| +33% | +$1.6M | 0.01% | 763 |
|
|
2021
Q2 | $5.76M | Buy |
35,576
+3,872
| +12% | +$627K | 0.01% | 815 |
|
|
2021
Q1 | $2.54M | Buy |
31,704
+11,414
| +56% | +$916K | ﹤0.01% | 1088 |
|
|
2020
Q4 | $1.1M | Sell |
20,290
-5,454
| -21% | -$297K | ﹤0.01% | 1455 |
|
|
2020
Q3 | $512K | Buy |
25,744
+5,169
| +25% | +$103K | ﹤0.01% | 1710 |
|
|
2020
Q2 | $432K | Sell |
20,575
-23,448
| -53% | -$492K | ﹤0.01% | 1789 |
|
|
2020
Q1 | $538K | Sell |
44,023
-15,614
| -26% | -$191K | ﹤0.01% | 1552 |
|
|
2019
Q4 | $875K | Buy |
59,637
+23,099
| +63% | +$339K | ﹤0.01% | 1557 |
|
|
2019
Q3 | $488K | Buy |
+36,538
| New | +$488K | ﹤0.01% | 1760 |
|
|
2018
Q4 | – | Sell |
-10,519
| Closed | -$301K | – | 2243 |
|
|
2018
Q3 | $301K | Buy |
10,519
+1,055
| +11% | +$30.2K | ﹤0.01% | 2106 |
|
|
2018
Q2 | $259K | Sell |
9,464
-5,327
| -36% | -$146K | ﹤0.01% | 2163 |
|
|
2018
Q1 | $312K | Buy |
+14,791
| New | +$312K | ﹤0.01% | 2040 |
|
|
2017
Q4 | – | Sell |
-22,640
| Closed | -$563K | – | 2259 |
|
|
2017
Q3 | $563K | Buy |
22,640
+10,137
| +81% | +$252K | ﹤0.01% | 1897 |
|
|
2017
Q2 | $200K | Buy |
+12,503
| New | +$200K | ﹤0.01% | 2129 |
|